You are here: Home Published Research Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Stephanie R Earnshaw, Cheryl L McDade, Giovanni Zanotti, Raymond A Farkouh, and David Strutton (2012)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

BMC infectious diseases, 12(1):101.

Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent pneumococcal conjugate vaccine (PCV10) are two recently approved vaccines for the active immunization against Streptococcus pneumoniae causing invasive pneumococcal disease in infants and children. PCV13 offers broader protection against Streptococcus pneumoniae; however, PCV10 offers potential protection against non-typeable Haemophilus influenza (NTHi). We examined public health and economic impacts of a PCV10 and PCV13 pediatric national immunization programs (NIPs) in Canada.

Adolescent, Adult, Aged, Canada, Child, Child, Preschool, Cost-Benefit Analysis, Drug Costs, Female, Haemophilus, Haemophilus Vaccines, Humans, Immunization Programs, Infant, Infant, Newborn, Male, Middle Aged, Pneumococcal Infections, Pneumococcal Vaccines, Prevalence, Streptococcus pneumoniae, Vaccines, Conjugate, Young Adult
Adolescent, Adult, Aged, Canada, Child, Child, Preschool, Cost-Benefit Analysis, Drug Costs, Female, Haemophilus, Haemophilus Vaccines, Humans, Immunization Programs, Infant, Infant, Newborn, Male, Middle Aged, Pneumococcal Infections, Pneumococcal Vaccines, Prevalence, Streptococcus pneumoniae, Vaccines, Conjugate, Young Adult
 
Document Actions